Provention Bio Inc. (PRVB)’s Financial Results Comparing With Enanta Pharmaceuticals Inc. (NASDAQ:ENTA)

This is a contrast between Provention Bio Inc. (NASDAQ:PRVB) and Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) based on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Provention Bio Inc. N/A 0.00 24.88M -0.74 0.00
Enanta Pharmaceuticals Inc. 238.40M 7.33 86.27M 3.65 20.53

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Provention Bio Inc. and Enanta Pharmaceuticals Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Provention Bio Inc. and Enanta Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Provention Bio Inc. 0.00% 0% 0%
Enanta Pharmaceuticals Inc. 36.19% 20.5% 19.3%


The Current Ratio and a Quick Ratio of Provention Bio Inc. are 53.7 and 53.7. Competitively, Enanta Pharmaceuticals Inc. has 23.7 and 23.7 for Current and Quick Ratio. Provention Bio Inc.’s better ability to pay short and long-term obligations than Enanta Pharmaceuticals Inc.

Analyst Recommendations

In next table is delivered Provention Bio Inc. and Enanta Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Provention Bio Inc. 0 0 0 0.00
Enanta Pharmaceuticals Inc. 0 0 1 3.00

Enanta Pharmaceuticals Inc. on the other hand boasts of a $80 consensus price target and a -11.00% potential downside.

Insider and Institutional Ownership

Institutional investors owned 6.7% of Provention Bio Inc. shares and 85.5% of Enanta Pharmaceuticals Inc. shares. Provention Bio Inc.’s share owned by insiders are 31%. Insiders Competitively, owned 3.6% of Enanta Pharmaceuticals Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Provention Bio Inc. 12.12% -23.82% -32.02% 0% 0% -46.15%
Enanta Pharmaceuticals Inc. -5.23% -11.4% -17.43% -37.76% 56.9% 27.81%

For the past year Provention Bio Inc. had bearish trend while Enanta Pharmaceuticals Inc. had bullish trend.


Enanta Pharmaceuticals Inc. beats on 10 of the 11 factors Provention Bio Inc.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.